Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice

Neurobiology of Disease

Volumn 41, Issue 2, 2011, Pages 436-444

  Simmons, Danielle A ^a,b   Mehta, Rishi A ^a,c   Lauterborn, Julie C ^a   Gall, Christine M ^a   Lynch, Gary ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST GEORGE S UNIVERSITY SCHOOL OF MEDICINE   (Grenada)

Author keywords

BDNF; DARPP 32; Huntingtin; Neuropathology; Neurotrophin; Rotarod; Striatum; Therapeutic

Indexed keywords

AMPA RECEPTOR AGONIST; AMPAKINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CX 929; HUNTINGTIN; NEUROTROPHIN; PHOSPHOPROTEIN DARPP 32; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DRUG HALF LIFE; GENOTYPE; HUNTINGTON CHOREA; IMMUNOREACTIVITY; LIFESPAN; LOCOMOTION; MALE; MOTOR PERFORMANCE; MOUSE; NEOCORTEX; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; ROTAROD TEST; SURVIVAL RATE; WESTERN BLOTTING;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ANTI-DYSKINESIA AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXCITATORY AMINO ACID AGONISTS; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; PHENOTYPE; RECEPTORS, AMPA; TREATMENT OUTCOME;

EID: 78650599933     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.10.015     Document Type: Article

References (64)

1. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., Lindsay R.M., Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
2. Apostol B.L., Simmons D.A., Zuccato C., Illes K., Pallos J., Casale M., Conforti P., Ramos C., Roarke M., Kathuria S., Cattaneo E., Marsh J.L., Thompson L.M. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol. Cell. Neurosci. 2008, 39:8-20.
3. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 14:805-810.
4. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl Acad. Sci. USA 2000, 97:6809-6814.
5. Bogush A., Pedrini S., Pelta-Heller J., Chan T., Yang Q., Mao Z., Sluzas E., Gieringer T., Ehrlich M.E. AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro. J. Biol. Chem. 2007, 282:7352-7359.
6. Bramham C., Messaoud E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog. Neurobiol. 2005, 76:99-125.
7. Canals J.M., Pineda J.R., Torres-Peraza J.F., Bosch M., Martin-Ibanez R., Munoz M.T., Mengod G., Ernfors P., Alberch J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 2004, 24:7727-7739.
8. Carter R., Lione L., Humby T., Mangiarini L., Mahal A., Bates G., Dunnett S., Morton A. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19:3248-3257.
9. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000, 23:387-392.
10. Chopra V., Fox J.H., Lieberman G., Dorsey K., Matson W., Waldmeier P., Housman D.E., Kazantsev A., Young A.B., Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl Acad. Sci. USA 2007, 104:16685-16689.
11. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 2005, 93:310-320.
12. Conner J.M., Lauterborn J.C., Yan Q., Gall C.M., Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and messenger RNA in the normal adult rat CNS: evidence for anterograde axonal transport. J. Neurosci. 1997, 17:2295-2313.
13. Davies S., Turmaine M., Cozens B., DiFiglia M., Sharp A., Ross C., Scherzinger E., Wanker E., Mangiarini L., Bates G. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
14. De March Z., Zuccato C., Giampà C., Patassini S., Bari M., Gasperi V., De Ceballos M.L., Bernardi G., Maccarrone M., Cattaneo E., Fusco F.R. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience 2008, 152:734-740.
15. Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., Matson W.R., Cooper A.J., Ratan R.R., Beal M.F., Hersch S.M., Ferrante R.J. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 2002, 22:8942-8950.
16. Deltheil T., Guiard B.P., Cerdan J., David D.J., Tanaka K.F., Reperant C., Guilloux J.P., Coudore F., Hen R., Gardier A.M. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55:1006-1014.
17. DiFiglia M., Sapp E., Chase K., Davies S., Bates G., Vonsattel J., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
18. Ehrnhoefer D.E., Duennwald M., Markovic P., Wacker J.L., Engemann S., Roark M., Legleiter J., Marsh J.L., Thompson L.M., Lindquist S., Muchowski P.J., Wanker E.E. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 2006, 15:2743-2751.
19. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
20. Fumagalli F., Di Pasquale L., Caffino L., Racagni G., Riva M.A. Repeated exposure to cocaine differently modulates BDNF mRNA and protein levels in rat striatum and prefrontal cortex. Eur. J. Neurosci. 2007, 26:2756-2763.
21. Gall C., Lauterborn J. Regulation of BDNF expression: multifaceted, region-specific control of a neuronal survival factor in the adult CNS. Neurobiology of the Neurotrophins 2000, 541-579. FP Graham Publishing Co., Johnson City, TN. I.M. (Ed.).
22. Gharami K., Xie Y., An J.J., Tonegawa S., Xu B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 2008, 105:369-379.
23. Greer J.J., Ren J. Ampakine therapy to counter fentanyl-induced respiratory depression. Respir. Physiol. Neurobiol. 2009, 168:153-157.
24. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 1999, 19:2522-2534.
25. Hatters D.M. Protein misfolding inside cells: the case of huntingtin and Huntington's disease. IUBMB Life 2008, 60:724-728.
26. Hickey M.A., Morton G.P., Reynolds A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 2002, 81:46-59.
27. Hickey M.A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M.S., Chesselet M.F. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008, 157:280-295.
28. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 2002, 51:235-242.
29. Hunt M.J., Morton A.J. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp. Brain Res. 2005, 166:220-229.
30. Ingvar M., Ambros-Ingerson J., Davis M., Granger R., Kessler M., Rogers G.A., Schehr R.S., Lynch G. Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 1997, 146:553-559.
31. Jin K., LaFevre-Bernt M., Sun Y., Chen S., Gafni J., Crippen D., Logvinova A., Ross C.A., Greenberg D.A., Ellerby L.M. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 2005, 102:18189-18194.
32. Kramar E.A., Chen L.Y., Lauterborn J.S., Simmons D.A., Gall C.M., Lynch G. BDNF upregulation rescues synaptic plasticity in middle-aged ovariectomized rats. Neurobiol. Aging 2010, (Epub ahead of print). 10.1016/j.neurobiolaging.2010.06.008.
33. Kuemmerle S., Gutekunst C.A., Klein A.M., Li X.J., Li S.H., Beal M.F., Hersch S.M., Ferrante R.J. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 1999, 46:842-849.
34. Landles C., Bates G.P. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep. 2004, 5:958-963.
35. Lauterborn J., Truong G., Baudry M., Bi X., Lynch G., Gall C. Chronic elevation of brain-derived neurotrophic factor by ampakines. J. Pharmacol. Exp. Ther. 2003, 307:297-305.
36. Lauterborn J.C., Pineda E., Chen L.Y., Ramirez E.A., Lynch G., Gall C.M. Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression. Neuroscience 2009, 159:283-295.
37. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948.
38. Li X.J. The early cellular pathology of Huntington's disease. Mol. Neurobiol. 1999, 20:111-124.
39. Li M., Huang Y., Ma A.A., Lin E., Diamond M.I. Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol. Dis. 2009, 36:413-420.
40. Luo S., Mizuta H., Rubinsztein D.C. p21-activated kinase 1 promotes soluble mutant huntingtin self-interaction and enhances toxicity. Hum. Mol. Genet. 2008, 17:895-905.
41. Lynch G. AMPA receptor modulators as cognitive enhancers. Curr. Opin. Pharmacol. 2004, 4:4-11.
42. Lynch G. Glutamate-based therapeutic approaches: ampakines. Curr. Opin. Pharmacol. 2006, 6:82-88.
43. Lynch G., Rex C.S., Gall C.M. LTP consolidation: substrates, explanatory power, and functional significance. Neuropharmacology 2007, 52:12-23.
44. Lynch G., Kramar E.A., Rex C.S., Jia Y., Chappas D., Gall C.M., Simmons D.A. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J. Neurosci. 2007, 27:4424-4434.
45. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S., Bates G. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
46. Matsumoto T., Rauskolb S., Polack M., Klose J., Kolbeck R., Korte M., Barde Y.A. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat. Neurosci. 2008, 11:131-133.
47. Matsuura K., Kabuto H., Makino H., Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 1997, 73:45-48.
48. Menalled L.B., Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 2002, 23:32-39.
49. Menalled L., El-Khodor B.F., Patry M., Suarez-Farinas M., Orenstein S.J., Zahasky B., Leahy C., Wheeler V., Yang X.W., MacDonald M., Morton A.J., Bates G., Leeds J., Park L., Howland D., Signer E., Tobin A., Brunner D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 2009, 35:319-336.
50. Murray T.K., Whalley K., Robinson C.S., Ward M.A., Hicks C.A., Lodge D., Vandergriff J.L., Baumbarger P., Siuda E., Gates M., Ogden A.M., Skolnick P., Zimmerman D.M., Nisenbaum E.S., Bleakman D., O'Neill M.J. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2003, 306:752-762.
51. Pallier P.N., Drew C.J., Morton A.J. The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: influence of non-motor factors on locomotor function. Brain Res. Bull. 2009, 78:347-355.
52. Peng Q., Masuda N., Jiang M., Li Q., Zhao M., Ross C.A., Duan W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 2008, 210:154-163.
53. Rex C.S., Lauterborn J.C., Lin C.Y., Kramar E.A., Rogers G.A., Gall C.M., Lynch G. Restoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factor. J. Neurophysiol. 2006, 96:677-685.
54. Rex C.S., Lin C.Y., Kramar E.A., Chen L.Y., Gall C.M., Lynch G. Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J. Neurosci. 2007, 27:3017-3029.
55. Simmons D.A., Casale M., Alcon B., Pham N., Narayan N., Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007, 55:1074-1084.
56. Simmons D.A., Rex C.S., Palmer L., Pandyarajan V., Fedulov V., Gall C.M., Lynch G. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc. Natl Acad. Sci. USA 2009, 106:4906-4911.
57. Stack E.C., Smith K.M., Ryu H., Cormier K., Chen M., Hagerty S.W., Del Signore S.J., Cudkowicz M.E., Friedlander R.M., Ferrante R.J. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 2006, 1762:373-380.
58. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003, 19:233-238.
59. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature 2000, 404:721-722.
60. van der Burg J.M., Bacos K., Wood N.I., Lindqvist A., Wierup N., Woodman B., Wamsteeker J.I., Smith R., Deierborg T., Kuhar M.J., Bates G.P., Mulder H., Erlanson-Albertsson C., Morton A.J., Brundin P., Petersen A., Bjorkqvist M. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2008, 29:41-51.
61. Vonsattel J., Myers R., Stevens T., Ferrante R., Bird E., Richardson E.J. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
62. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81:294-330.
63. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.
64. Zuccato C., Liber D., Ramos C., Tarditi A., Rigamonti D., Tartari M., Valenza M., Cattaneo E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 2005, 52:133-139.